September 2026
Oncostellae to Attend in BIO-Europe 2026 in Cologne

septiembre 2, 2026

---

Santiago de Compostela, Spain – September 2026 – Oncostellae, a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases,…

Read More

20 August 2026
Oncostellae Selected to Participate in ICEX Desafía Boston 2026

septiembre 2, 2026

---

Santiago de Compostela, Spain – 20 August 2026 – Oncostellae, a clinical-stage biopharmaceutical company developing innovative therapies for immune-mediated diseases, today…

Read More

30 July 2026
Oncostellae to Participate in the 26th Annual Biotech in Europe Forum in Basel organized by Sachs Associates

julio 30, 2026

---

Santiago de Compostela, Spain – 30 July 2026 – Oncostellae, a clinical-stage biotechnology company developing innovative therapies for immune-mediated diseases, today…

Read More

22 January 2026
Development of OST-499:
Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health

enero 22, 2026

---

Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health The company incorporates two…

Read More

5 September 2025
Oncostellae Strengthens Business Development Activities at BIO-Europe 2025 in Vienna

septiembre 5, 2025

---

Santiago de Compostela, Spain – 5 September 2025 – Oncostellae, a clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-mediated…

Read More

February 2025
Oncostellae Receives European Commission Seal of Excellence for OST-122 IBD Project

febrero 1, 2025

---

Santiago de Compostela, February 2025 – Oncostellae S.L., a clinical-stage biopharmaceutical company developing innovative therapies for immune-mediated and other diseases, announced…

Read More

29 February 2024
Oncostellae receives the STARTUP award at the Investing in Science 2024 Conference

febrero 29, 2024

---

El pasado jueves día 22 de febrero se le ha concedido a Oncostellae el premio STARTUP en el marco de las…

Read More

6 July 2023
Bio&Tech Smart Capital injects €500,000 into Oncostellae and joins the board

julio 6, 2023

---

Santiago-headquartered biopharmaceutical company Oncostellae has just wrapped up a funding round raising €3.3 million to complete Phase 2 clinical trials of…

Read More

15 December 2022
A biopharmaceutical company from A Coruña is developing a pioneering drug for ulcerative colitis

diciembre 15, 2022

---

A Coruña-based biopharmaceutical company Oncostellae is developing a new drug to treat ulcerative colitis, targeting patients with moderate to severe symptoms…

Read More

3 November 2022
The Galician company Oncostellae opens a €3.3 million capital increase to develop a drug for ulcerative colitis and a second one for colorectal cancer

noviembre 3, 2022

---

The Galician company Oncostellae opens a €3.3 million capital increase to develop a drug for ulcerative colitis and a second one…

Read More